Compare Stocks: ONCO, BDRX, CELZ, and PPCB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$1.47 -7.5%	$2.53	$1.02 ▼ $59.40	$3.17M	1.23	267,845 shs	34,671 shs
CELZ Creative Medical Technology	$1.15 +71.9%	$1.41	$0.62 ▼ $6.25	$3.17M	1.94	2.37 million shs	270.05 million shs
ONCO Onconetix	$0.90 -10.1%	$0.96	$0.67 ▼ $209.50	$1.15M	2.69	541,313 shs	392,815 shs
PPCB Propanc Biopharma	$1.37 +16.1%	$1.54	$0.95 ▼ $268.00	$2.69M	3.52	132,848 shs	1.22 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	-7.55%	-0.68%	-45.15%	-65.41%	-95.65%
CELZ Creative Medical Technology	+71.95%	+50.46%	+5.50%	-50.22%	-67.24%
ONCO Onconetix	-10.08%	+14.92%	-15.54%	-76.22%	-99.39%
PPCB Propanc Biopharma	+16.10%	+31.73%	-24.73%	-38.15%	-99.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$1.47 -7.5%	$2.53	$1.02 ▼ $59.40	$3.17M	1.23	267,845 shs	34,671 shs
CELZ Creative Medical Technology	$1.15 +71.9%	$1.41	$0.62 ▼ $6.25	$3.17M	1.94	2.37 million shs	270.05 million shs
ONCO Onconetix	$0.90 -10.1%	$0.96	$0.67 ▼ $209.50	$1.15M	2.69	541,313 shs	392,815 shs
PPCB Propanc Biopharma	$1.37 +16.1%	$1.54	$0.95 ▼ $268.00	$2.69M	3.52	132,848 shs	1.22 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	-7.55%	-0.68%	-45.15%	-65.41%	-95.65%
CELZ Creative Medical Technology	+71.95%	+50.46%	+5.50%	-50.22%	-67.24%
ONCO Onconetix	-10.08%	+14.92%	-15.54%	-76.22%	-99.39%
PPCB Propanc Biopharma	+16.10%	+31.73%	-24.73%	-38.15%	-99.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDRX Biodexa Pharmaceuticals	1.00	Sell	N/A	N/A
CELZ Creative Medical Technology	1.50	Reduce	N/A	N/A
ONCO Onconetix	1.00	Sell	N/A	N/A
PPCB Propanc Biopharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ONCO, BDRX, CELZ, and PPCB Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/31/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	PPCB Propanc Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/29/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/18/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/11/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/3/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
5/29/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
5/22/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/13/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
5/8/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDRX Biodexa Pharmaceuticals	$470K	6.26	N/A	N/A	$110.30 per share	0.01
CELZ Creative Medical Technology	$10K	545.10	N/A	N/A	$2.04 per share	0.56
ONCO Onconetix	$810K	1.27	N/A	N/A	$505.29 per share	0.00
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	$29.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDRX Biodexa Pharmaceuticals	-$8.42M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/11/2026 (Estimated)
CELZ Creative Medical Technology	-$5.99M	-$2.14	N/A	N/A	N/A	N/A	-88.38%	-84.71%	8/14/2026 (Estimated)
ONCO Onconetix	-$14.03M	$11.40	0.08	N/A	N/A	-1,316.28%	-101.08%	-47.34%	8/17/2026 (Estimated)
PPCB Propanc Biopharma	-$58.92M	-$24.25	N/A	N/A	N/A	N/A	-151.28%	-109.53%	N/A

Latest ONCO, BDRX, CELZ, and PPCB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	ONCO Onconetix	-$4,505.00	N/A	N/A	N/A	$0.02 million	N/A
8/14/2026	N/A	CELZ Creative Medical Technology	-$0.39	N/A	N/A	N/A	N/A	N/A
5/8/2026	Q1 2026	CELZ Creative Medical Technology	-$0.39	-$0.38	+$0.01	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
ONCO Onconetix	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDRX Biodexa Pharmaceuticals	N/A	2.03	2.03
CELZ Creative Medical Technology	N/A	19.67	19.67
ONCO Onconetix	N/A	1.41	1.37
PPCB Propanc Biopharma	N/A	2.37	2.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDRX Biodexa Pharmaceuticals	17.51%
CELZ Creative Medical Technology	1.42%
ONCO Onconetix	23.89%
PPCB Propanc Biopharma	N/A

Insider Ownership

Company	Insider Ownership
BDRX Biodexa Pharmaceuticals	0.34%
CELZ Creative Medical Technology	1.00%
ONCO Onconetix	0.27%
PPCB Propanc Biopharma	28.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDRX Biodexa Pharmaceuticals	20	2.00 million	1.99 million	Not Optionable
CELZ Creative Medical Technology	5	4.74 million	4.69 million	Not Optionable
ONCO Onconetix	12	1.14 million	1.14 million	N/A
PPCB Propanc Biopharma	1	2.28 million	1.63 million	Not Optionable

ONCO, BDRX, CELZ, and PPCB Headlines

Recent News About These Companies

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal ...

August 6 at 9:48 AM | markets.businessinsider.com

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

August 6 at 8:30 AM | globenewswire.com

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

August 5 at 8:30 AM | globenewswire.com

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

July 21, 2026 | globenewswire.com

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

July 7, 2026 | globenewswire.com

Propanc Biopharma launches $5M share repurchase program

July 2, 2026 | msn.com

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

July 2, 2026 | globenewswire.com

Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

June 16, 2026 | markets.businessinsider.com

Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

June 16, 2026 | globenewswire.com

PPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally?

June 13, 2026 | finance.yahoo.com

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

June 11, 2026 | globenewswire.com

Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an ...

June 2, 2026 | caledonianrecord.comC

Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

June 2, 2026 | markets.businessinsider.com

Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

June 2, 2026 | globenewswire.com

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

May 20, 2026 | markets.businessinsider.com

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

May 20, 2026 | globenewswire.com

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

May 19, 2026 | globenewswire.com

Propanc Biopharma, Inc. Reports Q3 Financial Results and Key Corporate Developments

May 15, 2026 | quiverquant.comQ

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

May 15, 2026 | globenewswire.com

Propanc Biopharma, Inc. Announces 1-for-25 Reverse Stock Split to Enhance Nasdaq Compliance

May 13, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO, BDRX, CELZ, and PPCB Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

$1.47 -0.12 (-7.55%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$1.51 +0.04 (+2.59%)

As of 08:17 AM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Creative Medical Technology NASDAQ:CELZ

$1.15 +0.48 (+71.95%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$1.36 +0.22 (+18.70%)

As of 08:24 AM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Onconetix NASDAQ:ONCO

$0.90 -0.10 (-10.08%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$0.91 +0.00 (+0.48%)

As of 08:22 AM Eastern

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Propanc Biopharma NASDAQ:PPCB

$1.37 +0.19 (+16.10%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$1.22 -0.15 (-10.95%)

As of 08:22 AM Eastern

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCO, BDRX, CELZ, and PPCB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCO, BDRX, CELZ, and PPCB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCO, BDRX, CELZ, and PPCB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO, BDRX, CELZ, and PPCB Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

Creative Medical Technology NASDAQ:CELZ

Onconetix NASDAQ:ONCO

Propanc Biopharma NASDAQ:PPCB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCO, BDRX, CELZ, and PPCB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCO, BDRX, CELZ, and PPCB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCO, BDRX, CELZ, and PPCB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO, BDRX, CELZ, and PPCB Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

Creative Medical Technology NASDAQ:CELZ

Onconetix NASDAQ:ONCO

Propanc Biopharma NASDAQ:PPCB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools